# C_2009320EN.01002601.xml

| 24.12.2009 | EN | Official Journal of the European Union | C 320/26 |
| --- | --- | --- | --- |

24.12.2009

EN

Official Journal of the European Union

C 320/26

---

Prior notification of a concentration

(Case COMP/M.5723 — Warburg Pincus/Novo/Archimedes Pharma JV)

Candidate case for simplified procedure

(Text with EEA relevance)

2009/C 320/13

| 1. | On 11 December 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Warburg Pincus Private Equity VIII OP and Warburg Pincus International Partners LP, controlled by Warburg Pincus & Co., USA, (‘Warburg Pincus’) and Novo Nordisk A/S and Novozymes A/S, wholly owned by the Novo Nordisk Foundation, Denmark, (‘Novo’) acquire within the meaning of Article 3(1)(b) of the Regulation joint control of Archimedes Pharma Ltd., United Kingdom, (‘Archimedes’) by way of purchase of shares. |
| --- | --- |

1.

On 11 December 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Warburg Pincus Private Equity VIII OP and Warburg Pincus International Partners LP, controlled by Warburg Pincus & Co., USA, (‘Warburg Pincus’) and Novo Nordisk A/S and Novozymes A/S, wholly owned by the Novo Nordisk Foundation, Denmark, (‘Novo’) acquire within the meaning of Article 3(1)(b) of the Regulation joint control of Archimedes Pharma Ltd., United Kingdom, (‘Archimedes’) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Warburg Pincus: A US based global private equity investor with investments focused on a range of sectors, including healthcare, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Warburg Pincus: A US based global private equity investor with investments focused on a range of sectors, including healthcare,

| — | for Novo: An institution that supports research in health science and art history primarily through the award of grants, |
| --- | --- |

—

for Novo: An institution that supports research in health science and art history primarily through the award of grants,

| — | for Archimedes: A hospital-focused specialty pharmaceutical group with established commercial operations and a portfolio of products focused on oncology, pain, neurology and critical care. |
| --- | --- |

—

for Archimedes: A hospital-focused specialty pharmaceutical group with established commercial operations and a portfolio of products focused on oncology, pain, neurology and critical care.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5723 — Warburg Pincus/Novo/Archimedes Pharma JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5723 — Warburg Pincus/Novo/Archimedes Pharma JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

(2)  OJ C 56, 5.3.2005, p. 32.

2

---